| Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M PL Woerther, C Burdet, E Chachaty, A Andremont Clinical microbiology reviews 26 (4), 744-758, 2013 | 912 | 2013 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 518 | 2021 |
| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet infectious diseases 22 (2), 209-221, 2022 | 388 | 2022 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 373 | 2021 |
| Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses H Pan, R Peto, AMH Restrepo, MP Preziosi, V Sathiyamoorthy, QA Karim, ... The Lancet 399 (10339), 1941-1953, 2022 | 289 | 2022 |
| Protection of the human gut microbiome from antibiotics J De Gunzburg, A Ghozlane, A Ducher, E Le Chatelier, X Duval, E Ruppé, ... The Journal of infectious diseases 217 (4), 628-636, 2018 | 170 | 2018 |
| Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia G Voiriot, B Visseaux, J Cohen, LBL Nguyen, M Neuville, C Morbieu, ... Critical Care 20, 1-9, 2016 | 161 | 2016 |
| The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022 | 157 | 2022 |
| Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled … A Dinh, J Ropers, C Duran, B Davido, L Deconinck, M Matt, O Senard, ... The Lancet 397 (10280), 1195-1203, 2021 | 135 | 2021 |
| An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 F Ader, N Peiffer-Smadja, J Poissy, M Bouscambert-Duchamp, D Belhadi, ... Clinical Microbiology and Infection 27 (12), 1826-1837, 2021 | 111 | 2021 |
| High-dose dexamethasone and oxygen support strategies in intensive care unit patients with severe COVID-19 acute hypoxemic respiratory failure: the COVIDICUS randomized … L Bouadma, A Mekontso-Dessap, C Burdet, H Merdji, J Poissy, C Dupuis, ... JAMA internal medicine 182 (9), 906-916, 2022 | 109 | 2022 |
| Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL) V Joly, C Burdet, R Landman, M Vigan, C Charpentier, C Katlama, ... Journal of Antimicrobial Chemotherapy 74 (3), 739-745, 2019 | 103 | 2019 |
| Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials A Amstutz, B Speich, F Mentré, CS Rueegg, D Belhadi, L Assoumou, ... The Lancet Respiratory Medicine 11 (5), 453-464, 2023 | 101 | 2023 |
| Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France P Loubet, N Lenzi, M Valette, V Foulongne, A Krivine, N Houhou, ... Clinical Microbiology and Infection 23 (4), 253-259, 2017 | 89 | 2017 |
| Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016 B Visseaux, C Burdet, G Voiriot, FX Lescure, T Chougar, O Brugière, ... PLoS One 12 (7), e0180888, 2017 | 75 | 2017 |
| Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review P Loubet, C Burdet, W Vindrios, N Grall, M Wolff, Y Yazdanpanah, ... Clinical microbiology and infection 24 (2), 125-132, 2018 | 71 | 2018 |
| Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives Q Le Hingrat, B Visseaux, C Laouenan, S Tubiana, L Bouadma, ... Clinical Microbiology and Infection 27 (5), 789. e1-789. e5, 2021 | 70 | 2021 |
| Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: what impact on intestinal colonisation … PL Woerther, R Lepeule, C Burdet, JW Decousser, É Ruppé, F Barbier International journal of antimicrobial agents 52 (6), 762-770, 2018 | 63 | 2018 |
| Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage E Ruppé, C Burdet, N Grall, V De Lastours, FX Lescure, A Andremont, ... Clinical Microbiology and Infection 24 (1), 3-5, 2018 | 62 | 2018 |
| Impact of antibiotic gut exposure on the temporal changes in microbiome diversity C Burdet, TT Nguyen, X Duval, S Ferreira, A Andremont, J Guedj, ... Antimicrobial agents and chemotherapy 63 (10), 10.1128/aac. 00820-19, 2019 | 57 | 2019 |
